Besides the main objective, there are 3 other objectives as follows:~To evaluate the anti-cancer effect of HM61713 in NSCLC patients with EGFR mutation~To investigate the pharmacokinetic profile of HM61713 and its metabolites after oral administration~To investigate biomarkers related to the safety and efficacy of HM61713
The main objective of this study is to evaluate the safety and tolerability of HM61713.